GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotage AB (OTCPK:BITGF) » Definitions » Forward PE Ratio

Biotage AB (Biotage AB) Forward PE Ratio : 0.00 (As of May. 01, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Biotage AB Forward PE Ratio?

Biotage AB's Forward PE Ratio for today is 0.00.

Biotage AB's PE Ratio without NRI for today is 53.72.

Biotage AB's PE Ratio for today is 53.72.


Biotage AB Forward PE Ratio Historical Data

The historical data trend for Biotage AB's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotage AB Forward PE Ratio Chart

Biotage AB Annual Data
Trend
Forward PE Ratio

Biotage AB Quarterly Data
Forward PE Ratio

Competitive Comparison of Biotage AB's Forward PE Ratio

For the Medical Instruments & Supplies subindustry, Biotage AB's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotage AB's Forward PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biotage AB's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Biotage AB's Forward PE Ratio falls into.



Biotage AB Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Biotage AB  (OTCPK:BITGF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Biotage AB Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Biotage AB's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotage AB (Biotage AB) Business Description

Traded in Other Exchanges
Address
Vimpelgatan 5, Box 8, Uppsala, SWE, 751 03
Biotage AB provides separation technology and solutions for analytical and organic chemistry from research to commercial analytical laboratories and industrial applications. Its customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research, and contract manufacturers as well as clinical, forensic, and academic laboratories in addition to organizations focused on food safety, clean water, and environmental sustainability. It serves three geographic markets: The Americas, APAC (Asia-Pacific,) and EMEA (Europe, Middle East & Africa). The company's product areas include Small Molecules & Synthetic Therapeutics, Biologics & Advanced Therapeutics, Scale-Up, Diagnostics, Analytical Testing, and Water & Environmental Testing.

Biotage AB (Biotage AB) Headlines

From GuruFocus

Biotage moves to the large cap segment

By PRNewswire PRNewswire 01-03-2022

Biotage AB (publ) Year-end report January - December 2021

By PRNewswire PRNewswire 02-11-2022

Biotage appoints Nomination Committee

By PRNewswire PRNewswire 09-24-2020

Biotage Awarded Gold Sustainability Medal by EcoVadis

By PRNewswire PRNewswire 02-24-2022

Biotage AB (publ) Interim report January - March 2021

By PRNewswire PRNewswire 04-28-2021

Biotage AB (publ) Year-End report January - December 2020

By PRNewswire PRNewswire 02-12-2021

Biotage AB (publ) publishes new Financial Goals

By PRNewswire PRNewswire 03-14-2022

Change in number of shares and votes

By PRNewswire PRNewswire 12-30-2021